Clinical trials: Vascular Patients
Hypertension
A Study Of Valsartan Used To Treat Hypertension For Up To 56 Weeks In Children Ages 1 - 5 Years Who Have Hypertension
Drugs used to treat hypertension in adults should also be effective in treating high blood pressure in infants and children. This study will test the safety and efficacy of valsartan in lowering blood pressure in children 1 - 5…
- Trial name
- NCT00171028
- Testing
- valsartan
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Novartis
Dose-Escalation Study, Relapsed or Refractory Multiple Myeloma
Phase 1 Study of F182112 in Patients With Relapsed or Refractory Multiple Myeloma
This trial is a Multiple center, Open-label, dose escalation Phase Ⅰ clinical study. The purpose is to evaluate the safety and tolerability of F182112 when infused intravenously (IV) and determine the maximum tolerated dose (MTD)…
- Trial name
- NCT04984434
- Testing
- F182112
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Coronary Artery Disease
Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Artery Lesions
The purpose of this study is to evaluate the safety, efficacy and deliverability of the CRE8 sirolimus-eluting stent system in the treatment of patients with de novo coronary artery lesions.
- Trial name
- NCT02360709
- Testing
- CRE8 sirolimus-eluting stent
- Where
- China
- Volunteers
- 800 people
- Sponsor
- CID S.p.A.
Cancer, Hematologic Malignancies
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone disease from multiple myeloma.
- Conditions
- Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology
- Trial name
- NCT01345019
- Testing
- Denosumab, Zoledronic acid, Denosumab (for the open-label treatment phase)
- Where
- 309 sites in United States, Australia and 27 more
- Volunteers
- 1,718 people
- Sponsor
- Amgen
Hypertension
A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension
This 16 week study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with moderate to severe high blood pressure in comparison to placebo.
- Trial name
- NCT00430638
- Testing
- olmesartan medoxomil + hydrochlorothiazide, if necessary
- Where
- 29 sites in United States
- Volunteers
- 278 people
- Sponsor
- Daiichi Sankyo
Diabetic Retinopathy
A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)
Diabetic retinopathy (DR) is a diabetes complication caused by damage to the small blood vessels inside the retina at the back of the eye. Diabetic retinopathy may cause mild vision problems or eventually blindness.
- Trial name
- ReFineDR (NCT04477707)
- Testing
- Finerenone (BAY94-8862)
- Where
- 62 sites in United States, Argentina and 13 more
- Volunteers
- 206 people
- Sponsor
- Bayer
Hypertension, Hyperlipidemias
A Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia
A multi-center, randomized, double-blind, phase III clinical trial to evaluate the efficacy and safety of Olmesartan/Amlodipine/Rosuvastatin combination treatment in patients with concomitant hypertension and hyperlipidemia
- Trial name
- NCT03009487
- Testing
- Amlodipine/Olmesartan 10/40mg (Combination drug), Rosuvastatin 20mg, Olmesartan 40 mg, Rosuvastatin 20mg, Amlodipine/Olmesartan 10/40mg (Combination drug)
- Where
- South Korea
- Volunteers
- 265 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Cardiac Surgery, Thoracic Surgery
Heart Lung Machine Registry
The HeaLMe post-market clinical follow-up registry is undertaken to evaluate the safety and performance of the index devices Heart Lung Machine HL 40 and Temperature Probes TPO-D-HLM L1.8 Adult / Pediatric in patients undergoing…
- Conditions
- Cardiac Surgery, Thoracic Surgery, Vascular Surgery, Cardiopulmonary Bypass
- Trial name
- HeaLMe (NCT06159517)
- Where
- 3 sites in Italy, Spain
- Volunteers
- 184 people
- Sponsor
- Maquet Cardiopulmonary GmbH
Healthy Volunteers, Relapsed Multiple Myeloma
A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
Part A: The purpose of Part A of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of RO7875913 in healthy participants.
- Conditions
- Healthy Volunteers, Relapsed Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT07342114
- Testing
- RO7875913, Cevostamab
- Where
- New Zealand
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Mild to Moderate Hypertension
A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension
The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacodynamics (PD) and pharmacokinetics (PK) of zilebesiran in Japanese patients with mild to moderate hypertension.
- Trial name
- NCT06423352
- Testing
- Zilebesiran
- Where
- 3 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Alnylam Pharmaceuticals
Fabry Disease
To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease
Primary Objective: To assess reduction of plasma lyso-GL3 level after switch to agalsidase beta from agalsidase alfa Secondary Objectives: To assess reduction of kidney podocyte GL3 content after switch to agalsidase beta from…
- Trial name
- BCLEAR1 (NCT04143958)
- Testing
- agalsidase beta (GZ419828), agalsidase alfa
- Sponsor
- Sanofi
Deep Vein Thrombosis, DVT
BOLT-DVT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis
The objective of this study is to demonstrate the safety and efficacy of the Indigo Aspiration system for percutaneous mechanical thrombectomy in a population presenting with obstruction due to deep vein thrombosis (DVT) who are…
- Trial name
- NCT05003843
- Testing
- Indigo Aspiration System
- Where
- 42 sites in United States
- Volunteers
- 229 people
- Sponsor
- Penumbra Inc.
Hypertension
Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)
Primary: To identify doses of Micardis®(telmisartan) which, administered once daily, are more effective than placebo and not inferior to HCTZ in lowering systolic blood pressure (SBP) in patients with isolated systolic…
- Trial name
- ARAMIS (NCT02175355)
- Testing
- Low dose of Micardis®, Medium dose of Micardis®, High dose of Micardis®
- Volunteers
- 1,039 people
- Sponsor
- Boehringer Ingelheim
Hypertension With Renal Dysfunction
Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction
This study assessed the safety, tolerability, and efficacy of LCZ696 in hypertensive patients with renal dysfunction.
- Trial name
- NCT01593787
- Testing
- LCZ696
- Where
- 13 sites in Japan
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals
Venous Leg Ulcer, Leg Ulcer
Efficacy Study for Geko Device in VLU Patients (Canada)
The objective of this study is to compare the efficacy of a daily geko™ wound therapy (duration of 12 hours), in conjunction with standard of care (SC), to SC alone, in participants with venous leg ulcers.The participants will go…
- Conditions
- Venous Leg Ulcer, Leg Ulcer, Venous Ulcer
- Trial name
- NCT05057793
- Testing
- geko
- Where
- 3 sites in Canada
- Volunteers
- 2 people
- Sponsor
- Firstkind Ltd
Hypertension
Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension
This is an open-label, non-comparative, multi-centre clinical study to evaluate the Efficacy and safety of Metoprolol Succinate prolonged-release tablet (Betaloc Zok) in patients with mild to moderate essential hypertension.
- Trial name
- NCT00861016
- Testing
- metoprolol succinate prolonged-release tablet and felodipine
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Pulmonary Hypertension, Sickle Cell Anemia
A Study of Patients Having Pulmonary Hypertension Associated With Sickle Cell Disease and Completing an ASSET Study
This study will assess the safety and efficacy of bosentan therapy (in a study known as ASSET) for patients who have high blood pressure in the lungs associated with sickle cell disease.
- Trial name
- ASSET-3 (NCT00360087)
- Testing
- Bosentan
- Volunteers
- 236 people
- Sponsor
- Actelion
Hereditary Angioedema, HAE
Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies
This is a phase 3b open-label study providing access to berotralstat for HAE patients who were previously enrolled in berotralstat studies.
- Trial name
- APeX-A (NCT04933721)
- Testing
- berotralstat
- Where
- 16 sites in Canada, Czechia and 9 more
- Volunteers
- 139 people
- Sponsor
- BioCryst Pharmaceuticals
Atrial Fibrillation
A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation
This study is a multicenter, randomized, subject and Investigator-blinded, placebo-controlled, parallel-group, multiple ascending dose-ranging study to evaluate the safety, tolerability, pharmacokinetics (PK), and…
- Trial name
- NCT04213807
- Testing
- MAA868 Cohort 1, MAA868 Cohort 2, MAA868 Cohort 3
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Anthos Therapeutics, Inc.
Locally Advanced Breast Cancer, Unresectable Breast Carcinoma
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 (also known as trastuzumab pamirtecan and DB-1303) in combination…
- Conditions
- Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer
- Trial name
- NCT06827236
- Testing
- BNT323, BNT327
- Where
- 81 sites in United States, Australia and 9 more
- Volunteers
- 380 people
- Sponsor
- BioNTech SE
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.